Trial · NCT05252845

Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults

NCT05252845, Phase 2, Completed, University of Oxford; results first posted 2025-07-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults. Trials, record NCT05252845. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05252845

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults
NCT number: NCT05252845
Status: Completed
Phases: Phase 2
Enrollment: 127 participants, actual
Lead sponsor: University of Oxford
Conditions: Malaria,Falciparum
Interventions: R21/Matrix-M vaccination, DHA-PIP, PQ
First posted: 2022-02-23
Last updated: 2025-07-03
Results first posted: 2025-07-03

Source ClinicalTrials.gov

Registered outcomes25

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification.	From the date of the first vaccination to 28 days after the last vaccination (up to approximately 1 month)
Primary	Occurrence of Serious Adverse Events (SAEs), According to the MedRA Classification.	During the whole study period, i.e. during a 6-month follow-up period from the receipt of first vaccination
Primary	Occurrence of Solicited Adverse Event Within 7 Days of Each Vaccination	Within 7 days of each vaccination.
Secondary	Number of Participants With Seroconversions in C-Term	at study Month 1	Number of Participants with Seroconversions in C-Term
Secondary	Number of Participants With Seroconversions in C-Term	at study Month 2	Number of Participants with Seroconversions in C-Term
Secondary	Number of Participants With Seroconversions in C-Term	at study Month 3	Number of Participants with Seroconversions in C-Term
Secondary	Number of Participants With Seroconversions in C-Term	at study Month 6	Number of Participants with Seroconversions in C-Term
Secondary	Number of Participants With Seroconversions in NANP	at study Month 1	Number of Participants with Seroconversions in NANP
Secondary	Number of Participants With Seroconversions in NANP	at study Month2	Number of Participants with Seroconversions in NANP
Secondary	Number of Participants With Seroconversions in NANP	at study Month 3	Number of Participants with Seroconversions in NANP

1 to 10 of 25Source ClinicalTrials.gov

See all 25 registered outcomes

Outcomes25

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification.	From the date of the first vaccination to 28 days after the last vaccination (up to approximately 1 month)	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Occurrence of Serious Adverse Events (SAEs), According to the MedRA Classification.	During the whole study period, i.e. during a 6-month follow-up period from the receipt of first vaccination	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Occurrence of Solicited Adverse Event Within 7 Days of Each Vaccination	Within 7 days of each vaccination.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Seroconversions in C-Term	at study Month 1	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Seroconversions in C-Term	at study Month 2	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Seroconversions in C-Term	at study Month 3	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Seroconversions in C-Term	at study Month 6	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Seroconversions in NANP	at study Month 1	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Seroconversions in NANP	at study Month2	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Seroconversions in NANP	at study Month 3	Participants	COUNT_OF_PARTICIPANTS

1 to 10 of 25Source ClinicalTrials.gov

See all 25 outcomes

Results by group69

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification.	R21/Matrix-M + DHA-PIP+PQ	17	Participants
Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification.	R21/Matrix-M Only	6	Participants
Occurrence of Unsolicited Adverse Events (AEs), According to the Medical Dictionary for Regulatory Activities (MedRA) Classification.	DHA-PIP+PQ Only	4	Participants
Occurrence of Serious Adverse Events (SAEs), According to the MedRA Classification.	R21/Matrix-M + DHA-PIP+PQ	1	Participants
Occurrence of Serious Adverse Events (SAEs), According to the MedRA Classification.	R21/Matrix-M Only	0	Participants
Occurrence of Serious Adverse Events (SAEs), According to the MedRA Classification.	DHA-PIP+PQ Only	1	Participants
Occurrence of Solicited Adverse Event Within 7 Days of Each Vaccination	R21/Matrix-M + DHA-PIP+PQ	37	Participants
Occurrence of Solicited Adverse Event Within 7 Days of Each Vaccination	R21/Matrix-M Only	36	Participants
Occurrence of Solicited Adverse Event Within 7 Days of Each Vaccination	DHA-PIP+PQ Only	0	Participants
Number of Participants With Seroconversions in C-Term	R21/Matrix-M + DHA-PIP+PQ	41	Participants

1 to 10 of 69Source ClinicalTrials.gov

See all 69 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	R21/Matrix-M + DHA-PIP+PQ	52
Overall Study	STARTED	R21/Matrix-M Only	53
Overall Study	STARTED	DHA-PIP+PQ Only	22
Overall Study	COMPLETED	R21/Matrix-M + DHA-PIP+PQ	48
Overall Study	COMPLETED	R21/Matrix-M Only	48
Overall Study	COMPLETED	DHA-PIP+PQ Only	20
Overall Study	NOT COMPLETED	R21/Matrix-M + DHA-PIP+PQ	4
Overall Study	NOT COMPLETED	R21/Matrix-M Only	5
Overall Study	NOT COMPLETED	DHA-PIP+PQ Only	2

Source ClinicalTrials.gov

Adverse events162

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Malaise	General disorders	R21/Matrix-M + DHA-PIP+PQ	4	52	4
other	Malaise	General disorders	R21/Matrix-M Only	3	53	3
other	Malaise	General disorders	DHA-PIP+PQ Only	0	22	0
other	Fever	Infections and infestations	R21/Matrix-M + DHA-PIP+PQ	14	52	16
other	Fever	Infections and infestations	R21/Matrix-M Only	9	53	9
other	Fever	Infections and infestations	DHA-PIP+PQ Only	1	22	1
other	ALT increased	Hepatobiliary disorders	R21/Matrix-M + DHA-PIP+PQ	4	52	4
other	ALT increased	Hepatobiliary disorders	R21/Matrix-M Only	0	53	0
other	ALT increased	Hepatobiliary disorders	DHA-PIP+PQ Only	0	22	0
other	Diarrhea	Gastrointestinal disorders	R21/Matrix-M + DHA-PIP+PQ	14	52	18

1 to 10 of 162Source ClinicalTrials.gov

See all 162 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	R21/Matrix-M + DHA-PIP+PQ	0	52
Total, all-cause mortality	R21/Matrix-M Only	0	53
Total, all-cause mortality	DHA-PIP+PQ Only	0	22
Total, other adverse events	R21/Matrix-M + DHA-PIP+PQ	38	52
Total, other adverse events	R21/Matrix-M Only	39	53
Total, other adverse events	DHA-PIP+PQ Only	5	22
Total, serious adverse events	R21/Matrix-M + DHA-PIP+PQ	1	52
Total, serious adverse events	R21/Matrix-M Only	0	53
Total, serious adverse events	DHA-PIP+PQ Only	1	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05252845

GET https://conductscience.org/api/trials/v1/NCT05252845/registered?page=2

API reference For AI assistants